Kestine 10 mg tabletti, kalvopäällysteinen Finlândia - finlandês - Fimea (Suomen lääkevirasto)

kestine 10 mg tabletti, kalvopäällysteinen

almirall sa - ebastine - tabletti, kalvopäällysteinen - 10 mg - ebastiini

Kestine Lyo 10 mg tabletti, kylmäkuivattu Finlândia - finlandês - Fimea (Suomen lääkevirasto)

kestine lyo 10 mg tabletti, kylmäkuivattu

almirall sa - ebastine - tabletti, kylmäkuivattu - 10 mg - ebastiini

Kestine 20 mg tabletti, kalvopäällysteinen Finlândia - finlandês - Fimea (Suomen lääkevirasto)

kestine 20 mg tabletti, kalvopäällysteinen

almirall sa - ebastine - tabletti, kalvopäällysteinen - 20 mg - ebastiini

Kestox 10 mg tabletti, kalvopäällysteinen Finlândia - finlandês - Fimea (Suomen lääkevirasto)

kestox 10 mg tabletti, kalvopäällysteinen

oy verman ab - ebastine - tabletti, kalvopäällysteinen - 10 mg - ebastiini

Kestox 20 mg tabletti, kalvopäällysteinen Finlândia - finlandês - Fimea (Suomen lääkevirasto)

kestox 20 mg tabletti, kalvopäällysteinen

oy verman ab - ebastine - tabletti, kalvopäällysteinen - 20 mg - ebastiini

Kestine Lyo 20 mg tabletti, kylmäkuivattu Finlândia - finlandês - Fimea (Suomen lääkevirasto)

kestine lyo 20 mg tabletti, kylmäkuivattu

almirall sa - ebastine - tabletti, kylmäkuivattu - 20 mg - ebastiini

Libtayo União Europeia - finlandês - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karsinooma, squamous cell - antineoplastiset aineet - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Livostin 0.5 mg/ml nenäsumute, suspensio Finlândia - finlandês - Fimea (Suomen lääkevirasto)

livostin 0.5 mg/ml nenäsumute, suspensio

mcneil / jntl consumer health (finland) oy - levocabastine - nenäsumute, suspensio - 0.5 mg/ml - levokabastiini

Livostin 0.5 mg/ml silmätipat, suspensio Finlândia - finlandês - Fimea (Suomen lääkevirasto)

livostin 0.5 mg/ml silmätipat, suspensio

mcneil / jntl consumer health (finland) oy - levocabastine - silmätipat, suspensio - 0.5 mg/ml - levokabastiini

Ocaliva União Europeia - finlandês - EMA (European Medicines Agency)

ocaliva

advanz pharma limited - obeticholic happo - maksakirroosi, biliary - bile- ja maksanhoito - ocaliva on tarkoitettu kohtelu primaari sapen sappitietulehdus (tunnetaan myös nimellä ensisijainen maksakirroosi) yhdessä ursodeoxycholic acid (udca) aikuisten riittävää vastetta udca tai monoterapiana aikuisilla sietäisi udca.